Post-doctoral position in Bruno Amati’s group

Oncogene addiction and targeted therapeutic development 

in MYC-driven B-cell lymphoma

A major research focus in the group is to unravel the molecular mechanisms underlying the oncogenic action of the MYC transcription factor (1-3) and exploit them for pre-clinical development of targeted therapies (4, 5). For example, our work revealed mitochondrial translation and respiratory activity as effective therapeutic targets in aggressive MYC-driven lymphomas: drugs that suppress these molecular processes show synthetic lethality with MYC activation in B-cells and strong anti-tumoral activity against B-cell lymphoma xenografts, especially when combined with BH3-mimetic compounds targeting select BCL2-family members (6-9). Through a combination of mechanism-driven hypotheses and high-throughput screens, we recently identified new molecular targets and compounds with equally promising potential against MYC-driven malignancies.

We seek to recruit an ambitious, motivated, team-oriented scientist with a PhD in life sciences. The successful candidate will address the therapeutic potential and mechanisms of action of select genes and drugs in MYC-associated lymphomas. The project will combine cell- and xenograft-based models with state-of-the-art molecular and genomic technologies, and will benefit from a highly integrated, multidisciplinary and supportive research environment. Prior experience in cellular, molecular and/or mouse biology will be an asset, but other specialty areas will also be positively considered. Spoken and written communication skills in English are required.